DUBLIN–(BUSINESS WIRE)–The “Global Stem Cell Umbilical Cord Blood (UCB) Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering.
The stem cell umbilical cord blood (UCB) market is poised to grow by $1.47 bn during 2022-2026, accelerating at a CAGR of 16.87% during the forecast period. The report on the stem cell umbilical cord blood (UCB) market provides a holistic analysis of market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of several chronic disorders, increased federal investment in stem cell therapy, and the advent of cord blood banking.
The stem cell umbilical cord blood (UCB) market analysis includes the end-user segment and geographic landscape.
The stem cell umbilical cord blood (UCB) market is segmented as below:
By End-user
- Pharmaceutical
- Research institutes
- Hospitals
- Biobanks
By Geographical Landscape
- North America
- Asia
- Europe
- Rest of World (ROW)
This study identifies the increasing investments in the field of regenerative medicines as one of the prime reasons driving the stem cell umbilical cord blood (UCB) market growth during the next few years. Also, increasing awareness, associated research, and potential clinical applications for stem cell and the rising emergence of personalized medicine will lead to sizable demand in the market.
The report on the stem cell umbilical cord blood (UCB) market covers the following areas:
- Stem cell umbilical cord blood (UCB) market sizing
- Stem cell umbilical cord blood (UCB) market forecast
- Stem cell umbilical cord blood (UCB) market industry analysis
Key Topics Covered:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by End-user
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Companies Mentioned
- Americord Registry LLC
- Athersys Inc.
- CBR Systems Inc.
- Cells4Life Group LLP
- Celularity Inc.
- Cordlife Group Ltd.
- Cryo Cell International Inc.
- Cryo Stemcell
- Cryoviva Biotech Pvt. Ltd.
- FamiCord Group
- FUTURE CELL JAPAN
- Global Cord Blood Corp.
- LifeCell International Pvt. Ltd.
- MEDIPOST Co. Ltd.
- Next Biosciences Pty Ltd.
- Regrow Biosciences Pvt Ltd.
- Smart Cells International Ltd.
- Smith and Nephew plc
- ViaCord LLC
- Vita 34 International AG
For more information about this report visit https://www.researchandmarkets.com/r/t8q5uh
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900